Illumina -- How the Business Works
Illumina is a $19.5B life sciences tools company that designs and manufactures next-generation
sequencing (NGS) instruments and consumables -- the dominant platform for reading DNA at scale.
The business follows a classic razor/blade model: place sequencing instruments (the razor) and
generate recurring, high-margin revenue from flow cells and reagents (the blade). Sequencing
consumables represent ~68% of total revenue and are the core earnings engine. The company
commands ~60-66% of global NGS installations, down from ~80% at peak dominance. Under CEO
Jacob Thaysen (since Nov 2023), Illumina completed the GRAIL spinoff (Sep 2024), simplified
operations, and is executing a cost restructuring while driving NovaSeq X adoption. FY2025
revenue was $4.34B (essentially flat YoY), with clinical consumables growing 20% ex-China in
Q4 2025 -- the standout growth vector. Calendar FY (Dec FYE). Composite score 5.9/10
(HOLD / Watchlist).
Price / Composite Score
$127.31 / 5.9
HOLD / Watchlist -- near 52-week highs, up 62% YoY
TTM Revenue
$4.34B
Flat YoY | Ex-China revenue grew 2% in FY2025
Trailing P/E
23.4x
Forward P/E 24.9x | EPS TTM $5.45
Analyst Target
$124.24 (-2%)
Consensus Hold | Next earnings May 7, 2026
Revenue mix -- consumables are the recurring engine
Product Revenue Breakdown (FY2025)
Sequencing Consumables (~68% of Revenue)
~$2,938M
Flow cells, reagent kits, library prep
Recurring revenue -- grows with installed base utilization
Instruments (~11%)
~$466M
NovaSeq X, MiSeq, NextSeq
The "razor" -- placed to drive consumable pull-through
Multiomics + Services (~21%)
~$936M
Spatial genomics, single-cell, proteomics, informatics
Emerging platforms and DRAGEN software/AI
Consumables ~68%
Instruments ~11%
Multiomics ~12%
Services ~9%
Sequencing Consumables Quarterly Trend -- Steady Growth Engine
Q1 2025
$696M
Flat YoY
Q2 2025
$740M
Flat YoY
Q3 2025
$747M
+1% YoY
Q4 2025
$755M
+8% YoY
The razor/blade model is the business. Illumina places sequencing instruments
(890 NovaSeq X units installed by end of 2025) and earns recurring revenue from consumables
as those instruments run samples. Consumables grew sequentially every quarter in 2025, reaching
$755M in Q4 (+8% YoY). The key metric is consumable pull-through per installed instrument --
as NovaSeq X replaces older systems, each unit generates higher consumable revenue due to
increased throughput. Clinical consumables grew 20% ex-China in Q4, indicating strong adoption
in the highest-value end market.
Revenue data from Illumina 10-K/10-Q filings and Daloopa. Product mix estimates from company earnings releases and analyst models.
How Illumina makes money -- the value chain
Illumina Value Chain -- From R&D to Recurring Revenue
R&D / Design
SBS/DRAGEN chemistry + optics
Proprietary sequencing chemistry = IP moat
→
Instrument Placement
NovaSeq X, MiSeq, NextSeq
890 NovaSeq X placed (Q4 2025)
→
Consumable Sales
Flow cells, reagents, library prep
~68% of revenue -- recurring, high-margin
→
Informatics / Software
DRAGEN, BaseSpace, Connected Analytics
AI/software layer captures more value per genome
→
Customer Segments
Clinical labs, research, population genomics
Clinical now majority of NGS market
Business Model Unit Economics and Scale
890
NovaSeq X Installed Base
100 placed in Q4 2025 alone
$2.94B
FY2025 Seq. Consumables Revenue
Up from $2.87B in FY2024
20%
Clinical Consumables Growth (Q4)
Ex-China -- the standout growth vector
$850M
Net Income (TTM)
Post-GRAIL margin recovery
NovaSeq X installed base and shipment data from Illumina earnings releases and Daloopa. Clinical consumables growth from Q4 2025 earnings call commentary.
Competitive landscape -- dominant but eroding oligopoly
Competitive Position Assessment (Oligopoly Gate: PASS -- but narrowing)
| Competitor | Platform | Threat Level | Competitive Dynamic |
|---|---|---|---|
| Short-Read Sequencing (Illumina Core -- ~60-66% Share) | |||
| Illumina (ILMN) | NovaSeq X, MiSeq, NextSeq | Incumbent leader | ~60-66% global share, dominant in clinical/regulated settings |
| Element Biosciences | AVITI | Medium | Open-chemistry model, strong in mid-throughput academic labs. Credible but small scale |
| Ultima Genomics | UG 100 | Medium | Validated $100 genome, forcing pricing pressure. Early commercial traction |
| Roche | SBX (launching 2026) | High | Most serious threat -- Roche diagnostics channel + regulatory expertise targets clinical moat directly |
| Long-Read Sequencing (Different Niche -- Complementary) | |||
| PacBio (PACB) | Revio | Low | Dominates HiFi long reads but different niche; financially stressed |
| Oxford Nanopore (ONT) | PromethION, MinION | Low | Portable/real-time niche; field epidemiology and point-of-care. Complementary |
| China Market (Locked Out) | |||
| BGI / MGI | DNBSEQ | Regional | Dominant in China; export restrictions limit ILMN access to China market (~$120-140M guided 2026) |
~60-66%
Global NGS Share
Down from ~80% at peak
Clinical Moat
IVD Approvals + Validation Costs
3-5 year switching barrier in regulated labs
Roche 2026
SBX Platform Launch
Most credible clinical challenger
Below Market
ILMN ~4-6% vs. 18%+ NGS CAGR
Growing slower = losing share
Oligopoly gate: PASS, but the moat is narrowing.
Illumina still controls ~60-66% of global NGS installations and dominates clinical/regulated
sequencing, where validation costs create massive switching barriers (3-5 year re-validation
cycles). However, market share has declined from ~80% at peak, and three credible challengers
are advancing: Element Biosciences in mid-throughput academic, Ultima Genomics forcing pricing
pressure with the $100 genome, and most importantly Roche launching its SBX platform in 2026
with direct access to clinical diagnostics channels. ILMN guided ~4-6% revenue growth for
2026 vs. an 18%+ overall NGS market CAGR -- a clear signal of ongoing share loss.
Market share estimates from analyst reports and management commentary. Competitive landscape from industry publications and earnings call transcripts. Roche SBX timeline from Roche investor communications.
Growth vectors and thematic tailwinds
Near-Term and Medium-Term Revenue Growth Drivers
| Growth Vector | Timeline | TAM Impact | Detail |
|---|---|---|---|
| Clinical Sequencing Adoption | Now | $100B+ TAM | 20% ex-China clinical consumables growth in Q4 2025. MRD, early cancer detection, CGP driving adoption. Reimbursement expanding |
| NovaSeq X Installed Base Growth | Now | Large | 890 units installed, 100 placed in Q4 alone. Each NovaSeq X drives higher consumable pull-through than predecessor platforms |
| Population Genomics Programs | 2025-2030 | Meaningful | UK NHS newborn WGS (~$650M), UK Biobank (490K genomes), NIH All of Us, Singapore PRECISE, Korea Bio-Big Data. Lumpy but large |
| Multiomics Expansion | 2026+ | Optionality | Spatial genomics, single-cell, proteomics -- extending beyond core sequencing. DRAGEN AI/software strategy. Early stage |
| Cost Restructuring | Now | Margin | Post-GRAIL spinoff simplification under CEO Thaysen. Operating leverage from cost cuts even on flat revenue |
| Genomics TAM Expansion | Secular | $42-72B by 2033 | Global NGS market at $11-13B in 2025, growing 18-21% CAGR. Oncology, liquid biopsy, pharmacogenomics, infectious disease |
TAM estimates from Illumina investor presentations and industry research. Population genomics program details from government publications and earnings call commentary. Clinical growth data from Q4 2025 earnings release.
Key risks to the business model
| Risk | Timeframe | Severity | Detail |
|---|---|---|---|
| Market Share Erosion | Ongoing | High | Share declined from ~80% to ~60-66%. Element, Ultima, and Roche (2026 SBX launch) are credible challengers. Growing below market rate |
| Roche SBX Platform | 2026 | High | Roche has diagnostics channel reach and regulatory expertise. Directly targets clinical sequencing -- where ILMN moat is strongest |
| China Revenue Decline | Structural | High | Export restrictions and local competition (BGI/MGI) have materially reduced China revenue. Guided to ~$120-140M in 2026 |
| Price Compression | Ongoing | Moderate | NovaSeq X delivers more throughput per dollar -- grows volumes but compresses per-unit consumable pricing. Ultima $100 genome forces deflation |
| Research Funding Uncertainty | Medium-term | Moderate | NIH budget pressures and academic spending caution. Research end-market remains soft while clinical inflects |
| Revenue Growth vs. Market | Structural | Moderate | FY2025 revenue was flat. 2026 guidance of ~4-6% growth substantially lags the 18%+ NGS market CAGR, implying continued share loss |
Risk assessment from Illumina 10-K, earnings calls, and analyst commentary. China guidance from FY2026 outlook. Roche SBX timeline from Roche investor communications.